Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vaxiflu-4
- Development stage
- Unknown
- Lead developer
- Zydus Lifesciences
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Vaxiflu-4 is a quadrivalent (tetravalent) inactivated split-virion influenza vaccine developed by Zydus Lifesciences (formerly Zydus Cadila). It is designed to provide protection against four seasonal influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The vaccine works by introducing inactivated (killed) viral antigens into the body, which stimulates the immune system to produce antibodies against the surface hemagglutinin of the targeted strains. Approved by India's DCGI and CDSCO, it was the first tetravalent inactivated influenza vaccine launched by an Indian pharmaceutical company. It is indicated for the prevention of seasonal influenza in individuals aged 6 months and older and is administered via intramuscular injection.
- Brand names
- Vaxiflu-4Vaxiflu4Vaxiflu 4
- Other names
- VaxiFlu-4VaxiFlu4VaxiFlu 4Tetravalent Inactivated Influenza Vaccine (Split Virion) IP
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Vaxiflu-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaxiflu-4.